This is the fifth Blog Post in a series examining Duchenne Muscular Dystrophy (DMD) in the rare disease and orphan drug space. This Blog Post discusses the EspeRare Foundation and how the organization is using repositioning or repurposing of an old drug to benefit DMD.
Drug repositioning or drug repurposing (DR) is applying existing drugs to new indications or diseases. DR is increasing in importance to many drug development and pharmaceutical companies. Using DR provides several advantages to companies:
• Repositioned drug has already passed toxicity and other tests
• Repositioned drug’s safety profile is already known
• Repositioned drug decreases the development time and cost of developing a drug.
Merck Serono, a division of Merck, announces in April 2013, the launch of the EspeRare Foundation. The EspeRare Foundation is presented to the public and international rare disease community at the IRDiRC (International Rare Diseases Research Consortium) Conference, in April…
View original post 336 more words